Retatrutide vs Tirzepatide: Triple vs Dual Agonist Compared

Both compounds sit in the incretin-pathway research space, but they are not interchangeable — the receptor targets, kinetics and research applications differ meaningfully.

Receptor profiles

Property	Retatrutide	Tirzepatide
Receptor targets	GIP, GLP-1, glucagon	GIP, GLP-1
Reported half-life	≈ 6 days	≈ 5 days
Vial size	10 mg lyophilized	10 mg lyophilized
Molecular weight	≈ 4,757 g/mol	≈ 4,813 g/mol

Retatrutide’s glucagon-receptor activity is the defining difference. Where tirzepatide research concentrates on glucose homeostasis and appetite regulation through the two incretin receptors, retatrutide protocols also touch energy expenditure and body-composition models that benefit from glucagon pathway involvement.

Research applications

• Tirzepatide — dual GIP/GLP-1 agonism is referenced in glucose-homeostasis studies, incretin signaling, and appetite-regulation models. It is widely used as a reference standard in receptor binding assays.
• Retatrutide — the added glucagon component makes it relevant to studies of simultaneous multi-receptor activation, energy expenditure, and metabolic pathway cross-talk that single- or dual-agonist compounds cannot address.

Reconstitution for both

Both ship as 10 mg lyophilized vials — the math is identical:

1. Choose a volume of USP bacteriostatic water (1–3 mL is a common research convention).
2. 10 mg = 10,000 µg; concentration = 10,000 ÷ water (mL) in µg/mL.
3. On a U-100 syringe, 1 unit = 0.01 mL, so a 2,000 µg dose from a 2 mL reconstitution is 40 units.

Use the retatrutide calculator or the tirzepatide calculator to compute any combination instantly.

Storage and handling

Both are lyophilized powders requiring −20 °C storage in dry form, reconstituted with bacteriostatic water, and handled under aseptic laboratory protocol. Full specifications are on each product page.

For laboratory research use only. Not medical advice.